Journal article
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis
Tomas Kalincik, Sifat Sharmin, Jennifer Massey, Ian Sutton, Barbara Withers, Mark S Freedman, Harold Atkins, Eva Krasulova, Eva Kubala Havrdova, Marek Trneny, Tomas Kozak, Joachim Burman, Richard MacDonell, Øivind Torkildsen, Lars Bø, Anne Kristine Lehmann, Basil Sharrack, John Snowden
Journal of Neurology, Neurosurgery and Psychiatry | BMJ Publishing Group | Published : 2024
Abstract
Background: Natalizumab was not shown to modify disability in progressive multiple sclerosis (MS). This matched observational study compared the effectiveness of autologous hematopoietic stem cell transplantation (AHSCT) with natalizumab in progressive MS. Methods: Patients with primary/secondary progressive MS from 7 AHSCT MS centres and the MSBase registry, treated with AHSCT or natalizumab were matched on a propensity score derived from sex, age, Expanded Disability Status Scale (EDSS), number of relapses 12/24 months before baseline, time from MS onset, the most effective prior therapy and country. The pairwise- censored groups were compared on hazards of 6-month confirmed EDSS w..
View full abstractGrants
Awarded by Biogen
Funding Acknowledgements
This research was funded in part by the National Health and Medical Research Council (1129189, 2026836) and Multiple Sclerosis Australia (19-800). For the purposes of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.